Topical thrombins: Benefits and risks

Pharmacotherapy

Volumn 29, Issue 7 PART 2, 2009, Pages

  Lomax, Christopher ^a,c   Traub, Oren ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Pacific Medical Centers   (United States)

^c NONE   (United States)

Author keywords

Black box warning; Bovine thrombin; Hemostasis; Postoperative coagulopathy; Thrombin

Indexed keywords

COLLAGEN; CROSS REACTING ANTIBODY; EVITHROM; FIBRINOGEN; GELATIN SPONGE; GELFOAM; HEMOSTATIC AGENT; RECOMBINANT THROMBIN; RECOTHROM; THROMBIN; UNCLASSIFIED DRUG;

BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SAFETY; HEMOSTASIS; HUMAN; IMMUNE MEDIATED COAGULOPATHY; INFECTION RISK; PLASMA; POSTOPERATIVE HEMORRHAGE; REVIEW; RISK ASSESSMENT; SAFETY; SURGICAL TECHNIQUE;

ADMINISTRATION, TOPICAL; ANIMALS; CATTLE; DRUG LABELING; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; INTRAOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; THROMBIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 68049136000     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.pt2.8S     Document Type: Review

References (34)

1. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001;233:88-96.
2. Doria C, Fischer CP, Wood CG, Li PM, Marra S, Hart J. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin 2008;24: 785-794
3. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 2007;205: 256-265 (Pubitemid 47095423)
4. Stassen JM, Arnout J, Deckmyn H. The hemostatic system. Curr Med Chem 2004;11:2245-2260
5. Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006;32(suppl 1):98-110.
6. King Pharmaceuticals, Inc. Thrombin-JMI (thrombin, topical U.S.P., bovine origin) package insert. Bristol, TN; 2007.
7. Johnson & Johnson Wound Management. Evithrom (thrombin, topical, human) package insert. Somerville, NJ; 2007.
8. Baxter Healthcare Corporation. Gelfoam Plus (gelatin sponge and human thrombin) package insert. Hayward, CA; 2007.
9. ZymoGenetics, Inc. Recothrom (thrombin, topical, recombinant) package insert. Seattle, WA; 2008.
10. Weaver FA, Lew W, Granke K, Yonehiro L, Delange B, Alexander WA. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg 2008;47:1266-1273
11. Seyednejad H, Imani M, Jamieson T, Seifalian AM. Topical haemostatic agents. Br J Surg 2008;95:1197-1225
12. Spotnitz WD. Active and mechanical hemostatic agents. Surgery 2007;142(suppl 4):S34-8.
13. Horowitz B, Busch M. Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin. Transfusion 2008;48:1739-1753
14. Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt- Jakob disease by blood and plasma products. Br J Haematol 2009;144:14-23.
15. Spotnitz WD, Burks S. Hemostats, sealants, and adhesives: components of the surgical toolbox. Transfusion 2008;48: 1502-1516
16. Terrab A, Pawlak D. Validation of a prion and virus purification process in the manufacture of bovine thrombin. J Applied Res 2007;7:217-226 (Pubitemid 350106778)
17. Jayapal KP, Wlaschin KF, Hu W-S, Yap MGS. Recombinant protein therapeutics from CHO cells-20 years and counting. American Institute of Chemical Engineers, CHO Consortium, Society for Biological Engineering (SBE) Special Section; 2007:40-7. Available from www.aiche.org/uploadedFiles/SBE/ Publications/CHO.pdf. Accessed February 9, 2009.
18. Sands JJ, Nudo SA, Ashford RG, Moore KD, Ortel TL. Antibodies to topical bovine thrombin correlate with access thrombosis. Am J Kidney Dis 2000;35:796-801.
19. Wai Y, Tsui V, Peng Z, Richardson R, Oreopoulos D, Tarlo SM. Anaphylaxis from topical bovine thrombin (Thrombostat) during haemodialysis and evaluation of sensitization among a dialysis population. Clin Exp Allergy 2003;33:1730-1734 (Pubitemid 38005395)
20. Warkentin TE. Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2007;21:589-607.
21. Bortoli R, Monticielo OA, Chakr RM, et al. Acquired factor XI inhibitor in systemic lupus erythematosus-case report and literature review [published online ahead of print May 31, 2008]. Semin Arthritis Rheum. Available from http://dx.doi.org/ 10.1016/j.semarthrit.2008.03.005.
22. Lee ES, Hibsman BK, Liebman HA. Acquired bleeding disorder in a patient with malignant lymphoma: antibody-mediated prothrombin deficiency. Cancer 2001;91:636-641 (Pubitemid 32173286)
23. Schoenecker JG, Johnson RK, Fields RC, et al. Relative purity of thrombin-based hemostatic agents used in surgery. J Am Coll Surg 2003;197:580-590
24. Dorion RP, Hamati HF, Landis B, Frey C, Heydt D, Carey D. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med 1998;122:887-894 (Pubitemid 28485270)
25. Crow SS, Sullivan VV, Aysola AE, et al. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg 2007;83:1547-1549 (Pubitemid 46440760)
26. Kapoor A, Cortese Hassett AL, Bontempo FA. Lack of response bleeding from acquired factor V inhibitor to recombinant human factor VIIa concentrate [abstract]. Blood 2005;106:105b-10.
27. Kirkeby KM, Aronowitz P. Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application [letter]. Am J Med 2005;118:805. (Pubitemid 40897676)
28. Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg 2005;79:1037-1038
29. Sarfati MR, Dilorenzo DJ, Kraiss LW, Galt SW. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg 2004;18:349-351
30. Savage WJ, Kickler TS, Takemoto CM. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatr Blood Cancer 2007;49:1025-1029
31. Shah AK, Moreno-Aspitia A. Acquired factor V inhibitor and single exposure to autologous growth factor. Thromb Res 2005;116:87-89 (Pubitemid 40546329)
32. Diesen DL, Lawson JH. Bovine thrombin: history, use, and risk in the surgical patient. Vascular 2008;16(suppl 1):S29-36.
33. Sands JJ, Nudo SA, Moore KD, Ortel TL. Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis. ASAIO J 2001;47:507-510
34. Terrab A, Pawlak D, Spaay P, Hoppensteadt D, Fareed J. Further removal of factor V-related antigen from bovine thrombin by utilizing a membrane-filtration step. Clin Appl Thromb Hemost 2008;14:135-140